- Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
- HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
- Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease
- First over-the-counter opioid overdose treatment approved by FDA
- NEC streamlines AI drug development with subsidiary reshuffle
- Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa
- Expansion of Scientific Affairs Group
- Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
- Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
- PHARMANOVIA EXPANDS EXCLUSIVE LICENSING COLLABORATION WITH AQUESTIVE THERAPEUTICS FOR DIAZEPAM BUCCAL FILM
- Unite Health: Thousands Honor Pandemic 'Influencers' Through COVID-19 Social Media Awards
- UK and Polish regulatory authorities approve Akari Therapeutics’ higher-yielding manufacturing process
- Hovione and Laxxon Medical sign partnership over 3D printed pharmaceutical applications
- Janssen reports new Rybrevant data for patients with advanced non-small cell lung cancer
- Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028